Metformin use before ICU admission in patients with severe lactic acidosis
Prognosis of Lactic Acidosis Upon Admission to Intensive Care According to the Existence of Prior Treatment With Metformin
This project will see if taking metformin before ICU admission changes survival for adults with type 2 diabetes who develop severe lactic acidosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07300293 on ClinicalTrials.gov |
What this trial studies
Researchers will review medical records of adults admitted to the CHU de Strasbourg intensive care unit between January 1, 2014 and December 31, 2023 who had lactic acidosis (pH <7.35 and lactate ≥5 mmol/L) within 24 hours of admission. Patients will be grouped by whether they had been taking metformin in the days before ICU admission and compared for ICU survival and related outcomes. The analysis will exclude patients without arterial blood gas data, unknown prior treatment, or who had therapy limitations within the first 24 hours. Results aim to clarify the association between prior metformin exposure and prognosis in this high-risk ICU population.
Who should consider this trial
Good fit: Adults (≥18 years) admitted to the CHU de Strasbourg ICU with documented lactic acidosis within 24 hours and a known pre-admission medication history including metformin use are ideal candidates for inclusion.
Not a fit: Patients without arterial blood gas measurements, with unknown prior medication history, or those who had limits placed on active therapy during the first 24 hours would not be expected to benefit from inclusion or the study's findings.
Why it matters
Potential benefit: If a link is found, clinicians could better judge risks of prior metformin use in critically ill patients and improve early management decisions.
How similar studies have performed: Previous observational studies on metformin and lactic acidosis have shown mixed and sometimes conflicting results, so the question remains unsettled.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years) * Admitted to the intensive care unit of Hautepierre Hospital - Strasbourg University Hospital between January 1, 2014, and December 31, 2023 * Having experienced lactic acidosis (pH \<7.35 and lactate level ≥5 mmol/L) within the first 24 hours of hospitalization. Exclusion Criteria: * Patient without arterial blood gas measurements during the first 24 hours of admission * whose background treatment is unknown and could not be determined * for whom a limitation of active therapies was implemented before or during the first 24 hours of hospitalization
Where this trial is running
Strasbourg
- Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Vincent CASTELAIN, MD, PhD
- Email: vincent.castelain@chru-strasbourg.fr
- Phone: 33 3.88.12.79.15
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.